Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Retained Earnings: 2022-2025

  • Abivax's Retained Earnings fell 65.66% to -$484.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$484.3 million, marking a year-over-year decrease of 65.66%. This contributed to the annual value of -$280.7 million for FY2024, which is 76.56% down from last year.
  • Abivax's Retained Earnings amounted to -$484.3 million in Q2 2025, which was down 6.04% from -$456.7 million recorded in Q1 2025.
  • Abivax's 5-year Retained Earnings high stood at -$84.4 million for Q4 2022, and its period low was -$484.3 million during Q2 2025.
  • In the last 3 years, Abivax's Retained Earnings had a median value of -$292.3 million in 2024 and averaged -$334.6 million.
  • Data for Abivax's Retained Earnings shows a maximum YoY crashed of 88.24% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Abivax's Retained Earnings stood at -$84.4 million in 2022, then tumbled by 88.24% to -$159.0 million in 2023, then plummeted by 76.56% to -$280.7 million in 2024, then tumbled by 65.66% to -$484.3 million in 2025.
  • Its Retained Earnings was -$484.3 million in Q2 2025, compared to -$456.7 million in Q1 2025 and -$280.7 million in Q4 2024.